Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10:16:2031-2039.
doi: 10.2147/PPA.S372366. eCollection 2022.

"It Was Very Comforting to Find Out Right Away." - Patient Perspectives on Point-of-Care Molecular SARS-CoV-2 Testing in Primary Care

Anni Matthes  1   2 , Florian Wolf  1 , Jutta Bleidorn  1 , Robby Markwart  1   2
Affiliations

"It Was Very Comforting to Find Out Right Away." - Patient Perspectives on Point-of-Care Molecular SARS-CoV-2 Testing in Primary Care

Anni Matthes et al. Patient Prefer Adherence. .

Abstract

Background: The use of point-of-care tests (POCTs) has been a central strategy to cope with the COVID-19 pandemic. Yet, evidence on the application and consequences of POCTs within medical settings is rare.

Purpose: To assess and understand patient perspectives on molecular point-of-care SARS-CoV-2 testing conducted in primary care.

Methods: We conducted a cross-sectional survey study among patients who were tested with a molecular SARS-CoV-2 rapid test (ID NOWTM COVID-19 rapid test, Abbott) in 13 primary care practices in the state of Thuringia (Germany) from February to April 2021. The following aspects were covered in the questionnaire through rating scales and open text formats: test characteristics, trust in test result, consequences of immediate result, cost amount willing to pay and expectations in the future. Open text answers were categorized; quantitative data were analyzed using descriptive statistics and a Mann-Whitney U-test to reveal differences in cost contribution depending on the test result.

Results: A total of 215 patients from nine family practices and one pediatric practice participated. The immediate availability of the test result was important to the majority of patients (94.3%). 95.7% of patients trusted in their test result. Personal consequences of the immediate test result referred to pandemic measures, certainty of action and reassurance. For further tests, patients were willing to pay between 0€ and 100€ (interquartile range = 10-25€) for the molecular SARS-CoV-2 POCT, regardless of the test result. Expectations of being offered the test again in case of renewed cold symptoms were reported by 96.2%.

Conclusion: Patients highly appreciated molecular SARS-CoV-2 rapid testing conducted in primary care practices. The immediate availability of the test result led to adjustments in patients' behavior and emotional wellbeing. However, potentially challenging for the implementation of POCTs in primary care practices may be the reimbursement of test costs and patients' expectations in future situation.

Keywords: COVID-19; POCT; acceptance; feasibility; rapid test.

PubMed Disclaimer

Conflict of interest statement

Ms Anni Matthes reports grants from the Ministry of Education and Research, during the conduct of the study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Patient’s rating of molecular SARS-CoV-2 rapid testing conducted in primary care practice. (A) Importance rating on test characteristics. (B) Approval rating on aspects concerning implementation of molecular SARS-CoV-2 rapid testing in primary care. Percentages within the bars are only presented if ≥3%.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Junker R, Schlebusch H, Luppa PB. Point-of-care testing in hospitals and primary care. Dtsch Arztebl Int. 2010;107(33):561–567. doi:10.3238/arztebl.2010.0561 - DOI - PMC - PubMed
    1. Luppa PB, Müller C, Schlichtiger A, Schlebusch H. Point-of-care testing (POCT): current techniques and future perspectives. Trends Analytical Chem. 2011;30(6):887–898. doi:10.1016/j.trac.2011.01.019 - DOI - PMC - PubMed
    1. German Federal Ministry of Health. National Testing Strategy SARS-Cov-2 [in German]. Berlin, Germany: German Federal Ministry of Health; 2022.
    1. Truong TT, Dien Bard J, Butler-Wu SM. Rapid Antigen Assays for SARS-CoV-2: promise and Peril. Clin Lab Med. 2022;42(2):203–222. doi:10.1016/j.cll.2022.03.001 - DOI - PMC - PubMed
    1. Davies E, Farooq HZ, Brown B, et al. An Overview of SARS-CoV-2 Molecular Diagnostics in Europe. Clin Lab Med. 2022;42(2):161–191. doi:10.1016/j.cll.2022.02.005 - DOI - PMC - PubMed